Why patient representation might harm science? by Cassidy, Jim
Introduction
The invitation to discuss this topic brings with it some
trepidation. In the current climate it is not ‘politically correct’
to take the stance that patients should be excluded from any
aspect of their care. So, from the outset I must declare that I
have some sympathy with patient representation, but I can
also see some problems and pitfalls. For the purposes of this
debate I have chosen to focus on these aspects, but will try
to balance this as we proceed.
Clinical science in the form of clinical trials is a slow and
laborious process. From concept to initiation, even a simple
clinical trial can take several years and involves repeated
applications for funding, peer review, ethics review and
several other processes. The recent adoption of European
Union directives on clinical trials has also added to this
burden. Principal investigators are usually highly qualified and
experienced individuals. They have taken the decision to lead
research because they are committed to making a difference
to patient care; otherwise, they could live out their working
lives in the National Health Service (in the UK context) or in
private practice (in most other countries). Although many
would contend that they only do it because there is some-
thing in it for them - perhaps peer approval, fame, or power - I
doubt that those rewards alone are sufficient motivation. This
is borne out by the fact that clinical trialists are always in the
minority of any professional health care grouping.
Why would we wish to involve patients?
Consultation of user groups/clients/customers is currently in
vogue in many aspects of life. In most cases this is useful to
obtain consumer advice about product or service qualities.
Although one could draw parallels between these individuals
and patients, I would contend that patients are not actually
customers. This is because, in my view, becoming a customer
is a voluntary process, whereas becoming a patient is as far
from voluntary as one could imagine. There is also the
implication in consumer feedback that things may change for
the better as a result of that feedback; I am not convinced
that this is realistic in many aspects of patient care. The
customer can also shop elsewhere if they are unhappy with
the product; once again, I am unconvinced that that fits with
reality when one considers the provision of health care. Most
of us are not within reasonable travelling distance of suitable
alternatives, especially if one considers therapy for most life-
threatening conditions.
What could patient representation add to this
already rigorous process?
The patient may be able to bring to the table some
consideration of project feasibility or acceptability. Although
the principal investigators usually work in the same
environment and one might expect them to have a clear view
on these matters, I would concede that this may not always
be true. However, does the patient representative really know
that much more? Each individual will bring their own personal
bias and in some cases they have some ‘axe to grind’. Later, I
shall return to this issue of how representative the patient can
be of the population in question.
The patient may also have the role of ‘protector’ in some
circumstances. Investigators can be so wrapped up in their
own ideas that they fail to see the risks and potential hazards
to patients (physical or psychological). I doubt that this is in
any way deliberate or premeditated. This role is also one of
the functions of ethics committees, so perhaps we do not
need extra protectors.
What damage could they do?
The selection (or self-selection) of a patient representative
causes me concern. How can they be truly representative?
They tend to be well educated professional people - not
quite the average person in my clinical practice in Glasgow.
Then, they get sent on various training courses and are
offered psychological support. They also become
experienced - and some might say ‘tamed’ - by association
with medical and allied health care professionals. This must
surely influence their opinions over time. This may not be
damaging, but it may take away any supposed value of the
representative.
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A patient representative may have a particular issue from their
own experience (or that of a loved one). This may cloud their
objectivity when attempting to generalize this experience to a
population. Extreme risk aversion may be an example.
Because all therapies we use can be toxic - some even fatal -
it is impossible to avoid all risk in clinical practice. Excessive
focus on just one aspect of outcome (such as quality of life)
may lead to over-emphasis on this point in trial design.
Patient representatives might make the process slower. Peer
review is already an extensive part of the trial development
process. Any further steps added will inevitably slow us down
and further diminish the clinical trial portfolio.
Their involvement is not free. They usually are paid and their
support structure is also financially subsidized. Who pays for
this? Could the monies have been used to support more trials?
Finally, it may be more difficult to design and execute clinical
trials that attempt to prove a principle and may have little or
no therapeutic benefit for the participants, the simplest
example being pharmacokinetic/pharmacodynamic studies in
humans.
Conclusion
Patient representation sounds like a good idea, but it does
have significant risks and pitfalls for clinical science.
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